2'-hydroxy-3'-nitro-3-biphenylcarboxylic acid

2'-hydroxy-3'-nitro-3-biphenylcarboxylic acid o loʻo faʻaaogaina e avea ma mea vavalalata o Eltrombopag .
Eltrombopag, atiina ae e GlaxoSmithKline (GSK) i Peretania ma mulimuli ane atiina ae soofaatasi ma Novartis i Suitiselani, o le muamua ma e naʻo le faʻatagaina laiti mole non peptide TPO receptor agonist i le lalolagi.Eltrombopag na faʻamaonia e le US FDA i le 2008 mo le togafitiga o le idiopathic thrombocytopenic purpura (ITP), ma i le 2014 mo togafitiga o le maʻi aplastic anemia (AA).O le vailaʻau muamua foʻi na faʻamaonia e le US FDA mo togafitiga o le AA i le 30 tausaga talu ai nei.
I le december2012, ua faamaonia e le US FDA Eltrombopag mo le togafitiga o thrombocytopenia i tagata mamaʻi ma hepatitis C (CHC), ina ia hepatitis C maʻi ma le le lelei prognosis ona o le maualalo platelet faitau e mafai ona amata ma tausia interferon faavae togafitiga tulaga mo maʻi ate.I le Fepuari3, 2014, GlaxoSmithKline na faʻasalalau e le FDA na tuʻuina atu le agavaa o vailaʻau faʻapitoa mo togafitiga o Eltrombopag mo togafitiga o le hemopenia i tagata mamaʻi e maua i le chemicalbook aplastic anemia (SAA) e leʻi tali atoatoa i le immunotherapy.I le aso 24 o Aokuso, 2015, na faʻamaonia ai e le US FDA Eltrombopag mo togafitiga o le thrombocytopenia i tagata matutua ma tamaiti e taʻi 1 tausaga ma sili atu ma le thrombocytopenia puipuia tumau (ITP) e le lava le tali atu i corticosteroids, immunoglobulins poʻo splenectomy.I le Ianuari 4, 2018, na faʻamaonia ai Eltrombopag e lisiina i Saina mo togafitiga o le thrombocytopenia puipuia muamua (ITP).